Literature DB >> 1441734

Immune response to hepatitis B vaccine in parenteral drug abusers.

J M Rodrigo1, M A Serra, L Aparisi, A Escudero, M S Gilabert, F García, R Gonzalez, J A del Olmo, A H Wassel, A Artero.   

Abstract

Responsiveness was assessed to a programme of vaccination of hepatitis B vaccine in a cohort of 197 intravenous drug addicts (mean age, 23.7 years) and their antibody response was compared with that of 271 healthy controls (mean age, 24.2 years). All participants were seronegative for hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs). The vaccination schedule consisted of three intramuscular injections (deltoid area) at months 0, 1 and 2. Although 70% of parenteral drug abusers received the three doses of vaccination, only 43.6% were evaluable for immune response. Fifty-eight per cent of heroin addicts and 80% of controls had evidence of anti-HBs seroconversion at 1 month after vaccination (chi 2 = 15.52, p less than 0.001). Geometric mean antibody titres were also significantly higher in controls (69.1 IU l-1; confidence interval 95%, 56.83 and 84.04) than in parenteral drug abusers (18.2 IU l-1; confidence interval 95%, 12.85 and 25.73) (F = 20.951, p less than 0.0001). The anti-HBs response was not influenced by coexistent anti-HBc, HCV antibody or HIV antibody seropositivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1441734     DOI: 10.1016/0264-410x(92)90516-m

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Vaccination could improve overall health in a high risk population.

Authors:  H Hagan
Journal:  West J Med       Date:  2000-01

2.  Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users.

Authors:  Thanh Q Tran; Carolyn Z Grimes; Dejian Lai; Catherine L Troisi; Lu-Yu Hwang
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

3.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

4.  Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens.

Authors:  Patricia M Flynn; Coleen K Cunningham; Bret Rudy; Craig M Wilson; Bill Kapogiannis; Carol Worrell; James Bethel; Dina Monte; Kelly Bojan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

5.  Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine.

Authors:  Ekaterina Moroz; Randy A Albrecht; Brandon Aden; Ann Bordwine Beeder; Jianda Yuan; Adolfo García-Sastre; Brian R Edlin; Mirella Salvatore
Journal:  Vaccine       Date:  2016-02-06       Impact factor: 3.641

6.  Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial.

Authors:  Lu-Yu Hwang; Carolyn Z Grimes; Thanh Quoc Tran; April Clark; Rui Xia; Dejian Lai; Catherine Troisi; Mark Williams
Journal:  J Infect Dis       Date:  2010-10-11       Impact factor: 5.226

7.  Dopamine D1 receptors within the basolateral amygdala mediate heroin-induced conditioned immunomodulation.

Authors:  Jennifer L Szczytkowski; Donald T Lysle
Journal:  J Neuroimmunol       Date:  2010-06-03       Impact factor: 3.478

8.  Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City.

Authors:  S Amesty; D C Ompad; S Galea; C M Fuller; Y Wu; B Koblin; D Vlahov
Journal:  J Community Health       Date:  2008-06

9.  A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers.

Authors:  Sylvia M Kiertscher; Pallavi R Gangalum; Grace Ibrahim; Donald P Tashkin; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2018-01-16       Impact factor: 4.147

10.  Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities.

Authors:  Sarah Bowman; Lauretta E Grau; Merrill Singer; Greg Scott; Robert Heimer
Journal:  BMC Public Health       Date:  2014-08-09       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.